An interventional study of Catheter Ablation for Atrial Fibrillation and Optimized Medical Therapy for Atrial Fibrillation in Atrial Fibrillation (AF), Atrial Fibrillation Ablation and Elderly, sponsored by Karolinska University Hospital. Recruiting at 2 sites in Sweden. Open to participants aged 78 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Karolinska University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Atrial Fibrillation with a site in Sweden — 24 open to participants now, 36 under way, 5 of them phase 3. Atrial Fibrillation · Sweden.
Among the 135 studies in Atrial Fibrillation with a site in Sweden, this one is the 53rd largest by planned enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2026, is one of 44 with no phase, reaches primary completion later than 33 of the 35 other live ones, and was the 131st registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →24 of the 135 studies in Atrial Fibrillation with a site in Sweden are open now. Recruiting first, the newest first:
Emma Svennberg · Sites in Sweden
Ages 18+
Rahul Raj · Sites in Sweden, Finland
Ages 18+
Region Stockholm · Sites in Sweden
Ages 55+
Johan Sundström · Sites in Sweden
Ages 50–75 · Healthy volunteers
Region Skane · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 78 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 30 · Phase 4 6
First in 1993; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 282 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 361 across the 95 interventional studies, 480 across the 39 observational. Of the 85 that completed or were terminated, 34 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 135 have an industry lead sponsor. The 10 most frequent:
Karolinska University Hospital is the lead sponsor of 279 studies on the registry; 55 are open to participants now.
Karolinska University Hospital has 5 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
5 of the studies in Atrial Fibrillation with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06696079Rahul RajRestarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation | 2026-12 |
| NCT04593498Karolinska InstitutetExcessive Supraventricular Activity and Atrial Fibrillation | 2026-12-31 |
| NCT06656884Boston Scientific CorporationFARAPULSE Workflow Assessment Registry | 2027-02-15 |
| NCT07181590Abbott Medical DevicesBaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF | 2027-09 |
| NCT06315192Region SkaneStroke Alarm Efficacy Trial | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 135 studies in Atrial Fibrillation with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ACE-AF is a multicenter randomized study in people aged 78 years and older with symptomatic atrial fibrillation (AF). AF is a common heart rhythm disorder in older adults and can cause reduced quality of life and lead to serious complications such as stroke and heart failure.
The study compares two established treatment strategies:
Participants are randomized 1:1 to one of these strategies. All participants will receive an implantable loop recorder (a small heart rhythm monitor placed under the skin) to continuously track heart rhythm and measure AF burden over time.
The study has two primary endpoints, tested with Holm-Bonferroni multiplicity control assessed over 24 months:
ACE-AF will provide evidence to guide treatment decisions for very elderly patients with symptomatic AF and help identify which patients benefit most from an ablation-based strategy compared with optimized medical therapy.
Background and Rationale
Atrial fibrillation (AF) is highly prevalent in very elderly individuals and is associated with substantial morbidity, including stroke, heart failure (HF), recurrent hospitalisations, polypharmacy, frailty, and impaired health-related quality of life (HRQoL). Catheter ablation is an established rhythm-control therapy in AF, but patients aged ≥78 years have been under-represented in randomised trials, and evidence on comparative effectiveness and safety versus optimised medical therapy in this age group remains limited. ACE-AF is designed to address this knowledge gap using a pragmatic randomised strategy design and continuous rhythm monitoring in both arms.
Study Design
ACE-AF is an investigator-initiated, multicentre, parallel-group, open-label randomised controlled trial conducted at seven Swedish university hospitals and collaborating centres in Denmark, Australia and Greece. Participants aged ≥78 years with symptomatic paroxysmal or persistent AF are randomised 1:1 to an ablation-based strategy or to optimised medical therapy without AF ablation.
Randomisation is performed centrally using an electronic system with allocation concealment until assignment, stratified by sex and age group (78-83 vs >83 years).
Study Arms and Interventions
Arm A: Catheter ablation strategy Catheter ablation is performed according to contemporary clinical practice at experienced centres.
Pulmonary vein isolation (PVI) is prioritised as the primary ablation strategy. Energy source and tools are selected according to local practice and operator discretion, without restriction to a specific technology.
Periprocedural management (imaging, anticoagulation, anaesthesia strategy) follows local standards of care and the study protocol.
Arm B: Optimised medical therapy strategy (no AF ablation) Guideline-directed rate and/or rhythm control tailored to clinical need, including antiarrhythmic drugs and/or cardioversion when appropriate.
AV-node ablation with pacemaker implantation is permitted when clinically indicated, according to standard care.
Treatment optimisation and follow-up adhere to protocol-defined principles and local clinical routines.
Rhythm monitoring (both arms)
All participants receive an implantable loop recorder (ILR) to enable continuous rhythm monitoring, including quantification of AF burden and detection of clinically relevant arrhythmias over time (ILR programming per protocol).
Study Flow and Follow-up
Screening/Baseline (pre-randomisation/visit 1): informed consent; baseline clinical assessment including comorbidity profiling; baseline questionnaires and planned assessments per protocol.
ILR implantation for continuous monitoring will be performed according to protocol-defined timing/workflow between the first and second visit.
Randomisation (1:1): central, concealed allocation; stratified by sex and age group (78-83 vs >83 years).
Intervention phase (visit 2):
Ablation arm: catheter ablation performed as per protocol and site standards. Control arm: initiation/optimisation of medical therapy; AV-node ablation with pacing permitted if clinically indicated.
Follow-up visits: scheduled follow-up visits are performed at approximately 3, 12, 18 and 24 months after randomisation/intervention, with continuous ILR surveillance throughout follow-up. At follow-up, clinical events, adverse events, treatment changes, and patient-reported outcomes are collected according to protocol, and ILR rhythm summaries are reviewed.
Primary Outcomes (two primary endpoints, tested with Holm-Bonferroni multiplicity control.)
The endpoints are evaluated over 24 months after randomisation and controlled for multiplicity using the Holm-Bonferroni procedure:
Composite clinical endpoint: all-cause mortality, stroke, serious bleeding, cardiac arrest, or hospitalisation due to heart failure within 24 months after randomisation.
HRQoL endpoint: effect on HRQoL measured by the RAND-36 "General Health" domain.
Secondary Outcomes
Secondary outcomes include (as specified in the protocol):
AF burden and rhythm outcomes (ILR-derived): AF burden over time, recurrence patterns, and detection of clinically relevant rhythm events.
Healthcare utilisation: hospitalisations and AF/HF-related care contacts.
Patient-reported outcomes: symptom burden and HRQoL using validated instruments (including RAND-36 and additional AF-related questionnaires per protocol).
Safety outcomes: procedure-related and treatment-related complications and serious adverse events.
Treatment pathways: need for cardioversion, medication escalation, AV-node ablation with pacing, and crossover patterns (as applicable).
Exploratory Objectives and Planned Subgroup/Modifier Analyses
Exploratory analyses will examine whether treatment effects differ by baseline characteristics and geriatric domains, including:
Frailty (e.g., Frailty Index and/or Clinical Frailty Scale).
Cognitive status (protocol-defined assessment).
Inflammatory biomarkers and overall comorbidity burden.
Sex (sex-disaggregated reporting and interaction analyses).
AF type (paroxysmal vs persistent).
Imaging substudy (selected Swedish sites): a predefined subgroup (e.g., at Karolinska and Linköping) planned for brain and/or cardiac imaging with MRI and/or CT per protocol to explore mechanistic associations.
Saliva sampling (optional subgroup): in a predefined subgroup, saliva is collected for exploratory biomarker/genetic analyses relevant to ageing and treatment response (separate consent; optional participation).
If subgroup analyses are underpowered, results will be reported as exploratory.
Sample Size and Statistical Considerations
The planned sample size is 282 participants, providing adequate power to detect clinically meaningful differences over 24 months, accounting for crossover and loss to follow-up. Primary analyses are performed according to the intention-to-treat principle. Multiplicity across the two primary endpoints is addressed using a pre-specified Holm-Bonferroni approach.
Safety Oversight
Participant safety is overseen by an independent Data Monitoring Committee (DMC), comprising senior cardiology researchers independent of the study (Professor Eva Swahn, Professor Lars Lund, and Professor Johan Engdahl). Safety monitoring and adverse event reporting are conducted throughout the study according to the protocol.
Ethics, Regulatory, and Data Protection
The study has been approved by the Swedish Ethical Review Authority (Dnr 2025-02305-01; decision date 12 May 2025); amendment approved 19 May 2026 (Dnr 2026-02894-02). Data are pseudonymised and processed in compliance with GDPR, with data captured in an electronic CRF (REDCap).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will undergo catheter ablation for atrial fibrillation, with pulmonary vein isolation (PVI) prioritized as the primary ablation strategy. Energy source and tools are selected according to local practice and operator discretion (no restriction to a specific technology). Participants will also receive an implantable loop recorder (ILR) for continuous rhythm monitoring throughout follow-up. Additional medical therapy may be used as clinically indicated according to guideline-based care.
Procedure: Catheter Ablation for Atrial Fibrillation · Drug: Optimized Medical Therapy for Atrial Fibrillation · Device: Implantable Loop Recorder (ILR)
Participants randomized to this arm will receive optimized guideline-directed medical therapy for atrial fibrillation without AF catheter ablation. Treatment may include rate control and/or rhythm control (including antiarrhythmic drugs and/or cardioversion when clinically appropriate). AV node ablation with pacemaker implantation is permitted when clinically indicated according to routine care. Participants will also receive an implantable loop recorder (ILR) for continuous rhythm monitoring throughout follow-up.
Drug: Optimized Medical Therapy for Atrial Fibrillation · Procedure: AV Node Ablation With Pacemaker implantation
Catheter ablation for symptomatic atrial fibrillation with pulmonary vein isolation (PVI) prioritized as the primary lesion set. Energy source and tools are selected according to local practice and operator discretion (no restriction to a specific technology), performed under routine standards of care at experienced centres.
Also known as: catheter ablation, pulmonary vein isolation
Guideline-directed rate and/or rhythm control tailored to the participant's clinical condition, including rate-control medications and/or antiarrhythmic drugs and cardioversion when clinically appropriate. AF ablation is not performed as part of this strategy.
Also known as: Guideline-directed medical therapy, Rate control, Rhythm control
Subcutaneous implantable loop recorder used for continuous rhythm monitoring and quantification of atrial fibrillation burden throughout follow-up. Implanted in all participants according to protocol-defined workflow.
AV node ablation with permanent pacing may be performed when clinically indicated according to routine care, as part of the optimized medical therapy strategy.
Composite clinical endpoint (all-cause mortality, stroke, serious bleeding, cardiac arrest, or heart failure hospitalization)
First part of the co-primary outcome: Proportion of participants with ≥1 of the following events within 24 months after intervention (visit 2): all-cause death, stroke, serious bleeding, cardiac arrest, or hospitalization for heart failure. Events will be adjudicated per protocol.
Time frame: 24 months after intervention (visit 2)
Change in RAND-36 General Health score
Second part of the co-primary outcome: Change from baseline in the RAND-36 "General Health" domain score at 24 months after the intervention (visit 2). Scores range 0-100; higher scores indicate better perceived health. Intention-to-treat. Because HRQoL is undefined after death, scores are not imputed for participants who die before the 24-month assessment; instead, deceased participants are assigned the worst rank (worst-rank / composite estimand, ICH E9(R1)) and the primary comparison uses a rank-based test. Missing data other than death are handled under a missing-at-random assumption with pre-specified sensitivity analyses.
Time frame: Baseline to 24 months after intervention (visit 2)
Differences of atrial fibrillation and atrial tachycardia burden (ILR-derived) between groups
Differences in percentage of time in atrial fibrillation and atrial tachycardia ("AF/AT burden") measured by continuous monitoring using an implantable loop recorder (ILR) between randomization groups.
Time frame: From date of ILR implantation (intervention day, visit 2) up to 30 months after implantation.
Hospitalizations (all-cause and cardiovascular)
Number of hospital admissions, including cardiovascular/AF-related hospitalizations, collected from clinical records.
Time frame: Up to 24 months after intervention
Serious adverse events and treatment-related complications
Serious adverse events (SAEs) and procedure-/treatment-related complications, including ablation-related and device-related complications, recorded and classified per protocol.
Time frame: Up to 24 months after intervention
Additional patient-reported outcomes (AF symptoms / disease-specific HRQoL)
Symptom burden and AF-related quality of life assessed using validated questionnaires specified in the protocol (e.g., ASTA and/or AFEQT, as applicable).
Time frame: Baseline and follow-up (3, 12, 18) through 24 months after intervention
Changes in Left atrial reservoir strain (LASr)
Left atrial function assessed as reservoir strain (LASr) by deformation imaging (speckle-tracking / deformation tracking, as per protocol). Reported as change from baseline to follow-up. Unit of measure: %
Time frame: Up to 12 months after intervention (visit 2)
Cognitive function measured by Montreal Cognitive Assessment (MoCA)
MoCA total score assessed at follow-up visits. Reported as change from baseline
Time frame: MoCA scores will be collected and assessed at baseline, 12, 18, and 24 months after intervention (visit 2).
Frailty score assessed by e-Frailty index
Frailty will be assessed using the e-Frailty index at baseline and follow-up. The outcome will be reported as a change in score from baseline to each follow-up time point.
Time frame: Up to 24 months after intervention; visit 2 ( 12, 18, and 24 months)
Discrimination of a prediction model for the ACE-AF primary composite outcome
A multivariable prediction model (using baseline clinical variables and AI-derived features) will be developed to predict the time to first occurrence of the ACE-AF primary composite clinical outcome.
Time frame: From baseline up to 24 months after intervention (visit 2).
Predictors of differential treatment effect on AF/AT burden
Baseline clinical variables (and AI-derived features, as available) will be evaluated as predictors of differential treatment effect on ILR-derived atrial fibrillation and atrial tachycardia (AF/AT) burden over follow-up.
Time frame: From implantation (visit 2) up to 30 months after intervention
Participants with at least one event in the composite neurological endpoint (dementia, stroke, intracranial hemorrhage)
Composite neurological endpoint defined as the first occurrence of any of the following during follow-up: 1. Incident dementia 2. Stroke (ischemic or hemorrhagic) 3. Intracranial hemorrhage (including intracerebral hemorrhage and subarachnoid hemorrhage, per protocol definition) Results will be reported as number and percentage of participants with ≥1 composite event during follow-up.
Time frame: Up to 24 months after intervention (visit 2).
Total healthcare costs per participant
Total direct healthcare costs per participant from intervention through follow-up, derived from healthcare utilization data (e.g., hospital inpatient/outpatient visits, procedures, emergency visits) and valued using standard regional/national tariffs per the health-economic analysis plan. Reported as mean/median cost per participant by group.
Time frame: Up to 24 months after intervention (visit 2)
All-cause mortality, stroke/TIA, serious bleeding, cardiac arrest, hospitalization due to heart failure analyzed separately
Time frame: Up to 24 months after intervention
Incident dementia
Proportion of participants with a new diagnosis of dementia during follow-up, based on predefined diagnostic criteria and/or registry/medical record confirmation.
Time frame: Up to 24 months after intervention (visit 2)
Discrimination of an inflammation proteomics-based prediction model for the ACE-AF primary composite outcome
A predefined subgroup of patients included in the County of Stockholm and Östergotland will be analyzed using a targeted inflammation proteomics panel. A prespecified inflammation proteomics score will be computed from the panel. The score combined with baseline clinical covariates will be used to develop a prediction model for time to first occurrence of the ACE-AF primary composite outcome event.
Time frame: Up to 24 months after intervention (visit 2).
Correlation between change in Epicardial fat and the combined AF/AT burden
Correlation between CT-derived Epicardial fat volume around LA the combined AF/AT burden measured by ILR through follow-up.
Time frame: From implantation (visit 2) up to 24 months after the intervention
Discrimination of a saliva proteomics-based prediction model for the primary composite outcome
In a predefined subgroup providing separate consent, saliva samples will be analyzed using a proteomics platform. A prespecified salivary proteomics score will be used to develop a prediction model for the first occurrence of the study primary composite outcome event from baseline.
Time frame: Baseline through 24 months after intervention
Change from baseline in oral health-related quality of life (OHIP-14 total score)
Patient-reported oral health-related quality of life measured using the Swedish version of the Oral Health Impact Profile (OHIP-14). The outcome will be reported as change from baseline in OHIP-14 total score.
Time frame: Up to 12 months after baseline visit
Plan to share: Yes — De-identified individual participant data underlying the reported results, plus a data dictionary, will be shared with researchers whose proposal is approved by the ACE-AF steering committee, under a signed data-access agreement and controlled access, in compliance with GDPR, Swedish law and the study's ethics approval.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 6 months after publication of the primary results and ending 5 years thereafter.
Access criteria: Methodologically sound proposal approved by the ACE-AF steering committee; signed data-access/transfer agreement; controlled access consistent with GDPR, Swedish law and ethics approval.
Started Oct 2026 (actual). Primary completion is estimated for Dec 2031, 62 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 62 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Karolinska University Hospital →